Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumours

Official Title

A Phase 1, Multicentre, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumours

Summary:

This is a Phase 1 open-label, multicentre study of the safety and tolerability, immunogenic effects, antitumour activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumours. The study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or vaginal cancer.

Trial Description

Primary Outcome:

  • Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0
  • Maximum tolerated dose (MTD)
  • Recommended Phase 2 dose (RP2D)
Secondary Outcome:
  • Antitumour activity
  • Manufacturing feasibility

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society